[{"uuid": "59b2df6b-5c06-314a-b552-8be524f7e948", "title": "Akoya Biosciences Selects Argonaut Manufacturing Services as IVD Manufacturing Partner", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/akoya-biosciences-selects-argonaut-manufacturing-110000858.html", "providerPublishTime": 1738062000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/kuz8_ad1wj3_TvLV81.3hw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/7b005a1f4d768157eb7a7bfc511d2062", "width": 1024, "height": 512, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/9Wbn95_lpCJLd1pCGB1aFg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/7b005a1f4d768157eb7a7bfc511d2062", "width": 140, "height": 140, "tag": "140x140"}]}}, {"uuid": "43bce6f1-6df0-343e-b01f-d1de3218e477", "title": "Canaccord Genuity Downgrades Akoya Biosciences to Hold From Buy, $3.50 Price Target", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/canaccord-genuity-downgrades-akoya-biosciences-122513253.html", "providerPublishTime": 1736771113, "type": "STORY", "relatedTickers": ["AKYA"]}, {"uuid": "068e8ac0-e6bf-3b80-b10d-e09302f36941", "title": "Top Premarket Decliners", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/top-premarket-decliners-132921065.html", "providerPublishTime": 1736774961, "type": "STORY", "relatedTickers": ["VMAR"]}, {"uuid": "2507eb80-2f4f-38c9-a9ee-e615e14dff3a", "title": "Quanterix Agrees to Acquire Akoya Biosciences in All-Stock Deal", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/quanterix-agrees-acquire-akoya-biosciences-124928754.html", "providerPublishTime": 1736513368, "type": "STORY", "relatedTickers": ["QTRX", "AKYA"]}, {"uuid": "c54586d4-436f-3edb-a2a3-76f6ea2cad93", "title": "Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/quanterix-acquire-akoya-biosciences-creating-120000428.html", "providerPublishTime": 1736510400, "type": "STORY", "relatedTickers": ["AKYA", "QTRX"]}, {"uuid": "8b892dbe-1096-309c-b080-5d11f647550c", "title": "Traders Digest Strong Jobs Growth as US Equity Futures Drop Pre-Bell", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/traders-digest-strong-jobs-growth-135509413.html", "providerPublishTime": 1736517309, "type": "STORY", "relatedTickers": ["^GDAXI", "^FTSE"]}, {"uuid": "963aaa10-916e-3f42-ac9e-4905a3a0cdaf", "title": "Top Premarket Gainers", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/top-premarket-gainers-125042568.html", "providerPublishTime": 1736513442, "type": "STORY", "relatedTickers": ["AKYA", "VMAR"]}, {"uuid": "9f54a137-1fed-3e5b-9e0e-eaefeaace2a9", "title": "Akoya Biosciences (AKYA) Reports Q3 Loss, Lags Revenue Estimates", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/akoya-biosciences-akya-reports-q3-221003152.html", "providerPublishTime": 1731622203, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/64vRzkiY9LXGPrpW4r2GRQ--~B/aD00Njc7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b95cfdd8768bc3c4620e666dbcb0b248", "width": 900, "height": 467, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/K_VbSLl5PAgBcdM4TzmL5A--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/b95cfdd8768bc3c4620e666dbcb0b248", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AKYA", "BRBR"]}, {"uuid": "62f8ce8f-2b95-38c1-bf82-973476e18397", "title": "Akoya Biosciences Secures Exclusive License for NeraCare's Immunoprint Test", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/akoya-biosciences-secures-exclusive-license-140310861.html", "providerPublishTime": 1733839390, "type": "STORY", "relatedTickers": ["AKYA"]}, {"uuid": "cad165bc-ff18-3407-a149-267f0272d550", "title": "Time To Worry? Analysts Just Downgraded Their Akoya Biosciences, Inc. (NASDAQ:AKYA) Outlook", "publisher": "Simply Wall St.", "link": "https://finance.yahoo.com/news/time-worry-analysts-just-downgraded-131121082.html", "providerPublishTime": 1731849081, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/dC75hPkPk1wNzUHQ29Af1A--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3", "width": 1194, "height": 432, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/6yvSv34WjsBU70VeapBSyg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2319011507a24b47a4bb11db126344d3", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AKYA"]}, {"uuid": "7e792c18-81ef-35d5-a518-fb7fec4b3f96", "title": "Nature Methods Names Spatial Proteomics \"Method of the Year 2024\" \u2014 Akoya Biosciences Celebrates Industry Milestone", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/nature-methods-names-spatial-proteomics-130000756.html", "providerPublishTime": 1733749200, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/HlPHD3iw6dc22v3aSGXhMg--~B/aD0zNzA7dz0xNDg5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/77d0f2caf972d5d9c3d584df2954d077", "width": 1489, "height": 370, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/c53RT8KeO8kOSNzKXGVudw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/77d0f2caf972d5d9c3d584df2954d077", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AKYA"]}, {"uuid": "ee973070-90a8-3a3f-bd35-b7bf58bad1d5", "title": "Akoya Biosciences Reports Third Quarter 2024 Financial Results", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/akoya-biosciences-reports-third-quarter-210000083.html", "providerPublishTime": 1731618000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/HlPHD3iw6dc22v3aSGXhMg--~B/aD0zNzA7dz0xNDg5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/77d0f2caf972d5d9c3d584df2954d077", "width": 1489, "height": 370, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/c53RT8KeO8kOSNzKXGVudw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/77d0f2caf972d5d9c3d584df2954d077", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AKYA"]}, {"uuid": "112f7e82-51d5-32ef-b8fa-b3ccde889967", "title": "Akoya Biosciences Inc (AKYA) Q3 2024 Earnings Report Preview: What To Look For", "publisher": "GuruFocus.com", "link": "https://finance.yahoo.com/news/akoya-biosciences-inc-akya-q3-122636752.html", "providerPublishTime": 1731500796, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/I3apxRFvcznv_pZA1c4yjw--~B/aD01MDQ7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/c158886780c37d41c83292f71d58668d", "width": 1242, "height": 504, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/sONeE20thOhKlpR2BcyQtQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/c158886780c37d41c83292f71d58668d", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AKYA"]}, {"uuid": "e16e74b8-3b54-38ee-b10c-2706282a689d", "title": "Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/akoya-biosciences-neracare-enter-exclusive-131500470.html", "providerPublishTime": 1733836500, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/HlPHD3iw6dc22v3aSGXhMg--~B/aD0zNzA7dz0xNDg5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/77d0f2caf972d5d9c3d584df2954d077", "width": 1489, "height": 370, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/c53RT8KeO8kOSNzKXGVudw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/77d0f2caf972d5d9c3d584df2954d077", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AKYA"]}, {"uuid": "a3dd21e9-b245-3aef-b7a9-519ad8108fc6", "title": "Akoya Biosciences Third Quarter 2024 Earnings: Misses Expectations", "publisher": "Simply Wall St.", "link": "https://finance.yahoo.com/news/akoya-biosciences-third-quarter-2024-130401629.html", "providerPublishTime": 1731762241, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c", "width": 945, "height": 636, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/NamfX5LEtyScIu4YmRG2hg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["AKYA"]}, {"uuid": "8c3ba224-8852-3fe2-a8b5-ef013839c582", "title": "Akoya Biosciences Inc (AKYA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ...", "publisher": "GuruFocus.com", "link": "https://finance.yahoo.com/news/akoya-biosciences-inc-akya-q3-071807670.html", "providerPublishTime": 1731655087, "type": "STORY", "relatedTickers": ["AKYA"]}, {"uuid": "ee4a0488-0dae-3893-be66-7c292e0c9ea1", "title": "Akoya: Q3 Earnings Snapshot", "publisher": "Associated Press Finance", "link": "https://finance.yahoo.com/news/akoya-q3-earnings-snapshot-210924501.html", "providerPublishTime": 1731618564, "type": "STORY", "relatedTickers": ["AKYA"]}, {"uuid": "aa5f2f3c-8e18-3e14-b0f5-cca0f79e5f3a", "title": "Wall Street Set to Open Lower Friday; Retail Sales Slightly Higher Than Expected", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/wall-street-set-open-lower-142143535.html", "providerPublishTime": 1731680503, "type": "STORY"}, {"uuid": "8c756353-d67f-3b5a-ba52-0cbf5c60ed55", "title": "Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/tarsus-pharmaceuticals-inc-tars-reports-223009093.html", "providerPublishTime": 1731537009, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/I67vygGrP1BjgOjVx.apeA--~B/aD03Mjg7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/b9775f315e7b6c4ada6e36d0048a929a", "width": 900, "height": 728, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/Qhyx0MmHdHV2_jvK0OQaCg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/b9775f315e7b6c4ada6e36d0048a929a", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["TARS"]}, {"uuid": "982df7be-daa6-36f1-a90c-3df2fb6414f9", "title": "Atara Biotherapeutics (ATRA) Reports Q3 Loss, Tops Revenue Estimates", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/atara-biotherapeutics-atra-reports-q3-221509126.html", "providerPublishTime": 1731449709, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/ZVGBNd2_.kAicju5mLde7g--~B/aD02MDA7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/71afbbc0512eb3c471136d93f39079c9", "width": 900, "height": 600, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/lCdXNO5h4hmjtS7ps0voGA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/71afbbc0512eb3c471136d93f39079c9", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["ATRA"]}]